Sulindac Indications, Contra Indications Sulindac Indications/ Sulindac is a sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. Sulindac is a sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects. Sulindac is a commonly used nonsteroidal anti-inflammatory drug (NSAID) that is available by prescription only and used predominantly to treat chronic arthritis. Sulidac is a rare, but the well-established cause of idiosyncratic, clinically apparent drug-induced liver disease. Mechanism of Action of Sulindac Sulindac’s exact mechanism of action is unknown. Its anti-inflammatory effects are believed to be due to inhibition of both COX-1 and COX-2 which leads to the inhibition of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in increased peripheral blood flow, vasodilation, and subsequent heat dissipation. or Sulindac is a prodrug that is converted to an active sulfide metabolite, which is responsible for most of the pharmacologic activity. The active metabolite of sulindac competitively inhibits both cyclooxygenase (COX) isoenzymes, COX-1 and COX-2, by blocking arachidonate binding resulting in analgesic, antipyretic, and anti-inflammatory pharmacologic effects. The parent drug has a minimal inhibitory effect on COX; the sulfide metabolite is 500 times more potent. The enzymes COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin G2 (PGG2), the first step of the synthesis prostaglandins and thromboxanes that are involved in rapid physiological responses. COX isoenzymes are also responsible for a peroxidase reaction, which is not affected by NSAIDs. In addition, NSAIDs do not suppress leukotriene synthesis by lipoxygenase pathways. COX-1 is constitutively expressed in almost all tissues, while COX-2 appears to only be constitutively expressed in the brain, kidney, bones, reproductive organs, and some neoplasms (e.g., colon and prostate cancers). COX-1 is responsible for prostaglandin synthesis in response to stimulation by circulating hormones, as well as maintenance of normal renal function, gastric mucosal integrity, and hemostasis. However, COX-2 is inducible in many cells in response to certain mediators of inflammation (e.g., interleukin-1, tumor necrosis factor, lipopolysaccharide, mitogens, and reactive oxygen intermediates). FDA Level Anti-inflammatory Activity – The anti-inflammatory mechanism of sulindac is due to decreased prostaglandin synthesis via inhibition of COX-1 and COX-2. It appears that the anti-inflammatory effects may be primarily due to inhibition of the COX-2 isoenzyme. However, COX-1 is expressed at some sites of inflammation. COX-1 is expressed in the joints of rheumatoid arthritis or osteoarthritis patients, especially the synovial lining, and it is the primary enzyme of prostaglandin synthesis in human bursitis. Sulindac is considered a non-selective NSAID; however, it is highly selective for the COX-1 isoenzyme. Analgesic Activity – Sulindac is effective in cases where inflammation has caused the sensitivity of pain receptors (hyperalgesia). It appears prostaglandins, specifically prostaglandins E and F, are responsible for sensitizing the pain receptors; therefore, sulindac has an indirect analgesic effect by inhibiting the production of further prostaglandins and does not directly affect hyperalgesia or the pain threshold. Antipyretic Activity – Sulindac promotes a return to a normal body temperature set point in the hypothalamus by suppressing the synthesis of prostaglandins, specifically PGE2, in circumventricular organs in and near the hypothalamus. Sulindac may mask fever in some patients, especially with high or chronic dosing. GI Effects – Gastrointestinal side effects of sulindac are primarily contributed to COX-1 inhibition; however, the potential role of COX-2 inhibition in the GI tract has not been fully elucidated. Platelet Effects – The inhibition of platelet aggregation seen with sulindac is due to a dose-dependent inhibition of COX-1 in platelets leading to decreased levels of platelet thromboxane A2 and an increase in bleeding time (see Adverse Reactions). The inhibition of platelet aggregation is reversible within 24 hours of discontinuation of sulindac. This differs from aspirin, which irreversibly binds to COX-1 in platelets inhibiting this enzyme for the life of the cell. Renal Effects: In the kidney, prostaglandins, produced by both COX-1 and COX-2, are important regulators of sodium and water reabsorption through PGE2 and of renal function and hemodynamics via PGI2 in response to vasoconstrictive factors (e.g., endothelin-1, a factor that increases peripheral vascular resistance) and through effects on the renin-angiotensin system. In conditions where renal blood flow is dependent upon prostaglandin synthesis, administration of NSAIDs can result in significant decreases in renal blood flow leading to acute renal failure. In addition, alterations in sodium and water reabsorption may worsen increased blood pressure, which can be significant in selected individuals. Sulindac Indications For acute or long-term use in the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis Ankylosing Spondylitis Tendonitis Rheumatoid arthritis Osteoarthritis Acute and chronic rheumatoid arthritis, Mild to moderate pain associated with musculotendinous trauma sprains and strains Postpartum pain. Treatment of some pain, especially nerve pain such as Sciatica, Postherpetic neuralgia Referred pain for radiculopathy. Pauciarticular juvenile rheumatoid arthritis Polyarticular juvenile rheumatoid arthritis, chronic or unspecified Frozen shoulder Pain with itching, Tendonitis Bursitis Sulindac Contra-Indications Systemic mastocytosis Increased risk of bleeding due to a clotting disorder Alcoholism High blood pressure Chronic heart failure Disease of the heart and blood vessels Stroke Ulcer from stomach acid Stomach or intestinal ulcer Liver problems Bleeding of the stomach or intestines Kidney stone Systemic lupus erythematosus Visible water retention Pregnancy A mother who is producing milk and breastfeeding A rupture in the wall of the stomach or intestine Increased cardiovascular event risk Time immediately after coronary bypass surgery chronic kidney disease stage 4 (severe A mother who is producing milk and breastfeeding Dosages of Sulindac Strengths: 150 mg; 200 mg Rheumatoid Arthritis Initial dose: 150 mg orally twice a day Maximum dose: 400 mg orally per day Osteoarthritis Initial dose: 150 mg orally twice a day Maximum dose: 400 mg orally per day Ankylosing Spondylitis Initial dose: 150 mg orally twice a day Maximum dose: 400 mg orally per day Acute Gout Initial dose: 200 mg orally twice a day Maximum dose: 400 mg orally per day Duration of therapy: 7 days is usually adequate Bursitis Initial dose: 200 mg orally twice a day Maximum dose: 400 mg orally per day Duration of therapy: 7 to 14 days is usually adequate Tendonitis Initial dose: 200 mg orally twice a day Maximum dose: 400 mg orally per day Duration of therapy: 7 to 14 days is usually adequate Side Effects of Sulindac The common stomach pain abdominal or stomach pain, cramping, or burning (severe) bloody or black, tarry stools blurred vision or any change in vision chest pain allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue convulsions (seizures) fast or irregular breathing fast, irregular heartbeat or pulse indigestion nausea, vomiting diarrhea More common Acid or sour stomach constipation headache heartburn nausea or vomiting skin rash stomach pain constipation gas rash Less common Excess air or gas in the stomach or intestines itching skin passing gas stomach cramps swelling weight loss diarrhea indigestion or heartburn nausea dizziness headache itching or rash Rare Anxiety change in vision seizures abnormal or fast heart rate weight loss chest pain or tightness confusion cough Agitation arm, back, or jaw pain blurred vision chest pain or discomfort convulsions extra heartbeats hallucinations headache irritability muscle pain or cramps pale or yellowed skin, dark colored urine, fever, confusion or weakness; jaundice (yellowing of the skin or eyes); sore throat, and headache with a severe blistering peeling, and red skin rash; swelling, rapid weight gain, feeling short of breath (even with mild exertion); or increased thirst, loss of appetite, urinating less than usual or not at all. Drug Interactions of Sulindac Sulindac may interact with following drugs, supplements & may change the efficacy of drugs aminoglycoside antibiotics (e.g., amikacin, gentamicin, tobramycin) angiotensin-converting enzyme (ACE) inhibitors (e.g., ramipril, enalapril, captopril, quinapril) angiotensin receptor blockers (ARBs; e.g., candesartan, irbesartan, losartan) “azole” antifungals (e.g., itraconazole, ketoconazole, voriconazole) beta-adrenergic blockers (e.g., atenolol, propranolol, sotalol) bisphosphonates (e.g., alendronate, etidronate) carbamazepine celecoxib cilostazol clopidogrel cyclosporine dabigatran dasatinib diuretics (water pills; e.g., furosemide, hydrochlorothiazide, triamterene) fluvastatin haloperidol heparin ibrutinib methotrexate multivitamins (with vitamins A, E) with or without minerals nilotinib non-steroidal anti-inflammatory medications (NSAIDs; e.g., diclofenac, ibuprofen, naproxen) omega-3 fatty acids omeprazole oral corticosteroids (e.g., dexamethasone, hydrocortisone, prednisone) pentoxifylline phenobarbital phenytoin quinolone antibiotics (e.g., ciprofloxacin, norfloxacin, ofloxacin) selective serotonin reuptake inhibitors (SSRIs; e.g., citalopram, duloxetine, fluoxetine, paroxetine, sertraline) serotonin/norepinephrine reuptake inhibitors (SNRIs; e.g., duloxetine, venlafaxine) sulfasalazine tricyclic antidepressants (e.g., amitriptyline, clomipramine, desipramine, trimipramine Pregnancy & Lactation of Sulindac Sulindac falls into category C before the 30th week of pregnancy, and category D after the 30th week. Pregnancy For Pregnancy Category C before the 30th week of pregnancy: Studies in animals have shown a harmful and undesired effect on the unborn baby, yet there are no adequate and well-controlled studies in pregnant women. This medication may be given to a pregnant woman if her healthcare provider believes that its benefits to the pregnant woman outweigh any possible risks to her unborn baby. For Pregnancy Category D after the thirtieth week of pregnancy: Sulindac should be avoided during the third trimester of pregnancy. There is evidence of risk to the unborn baby based on studies in humans or adverse reaction data. Lactation Tell your doctor if you are breastfeeding or plan to breastfeed. It is not known if sulindac is excreted in human breast milk or if it will harm your nursing baby. References ChemIDplus https://chem.nlm.nih.gov/chemidplus/sid/0032004685 https://chem.nlm.nih.gov/chemidplus/sid/0038194502 https://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp DTP/NCI https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=757344 DrugBank http://www.drugbank.ca/drugs/DB00605 http://www.drugbank.ca/drugs/DB00605#carriers http://www.drugbank.ca/drugs/DB00605#targets http://www.drugbank.ca/drugs/DB00605#enzymes http://www.drugbank.ca/drugs/DB00605#transporters https://www.drugs.com/mtm/sulindac.html EPA DSStox https://comptox.epa.gov/dashboard/dsstoxdb/results?search=DTXSID4023624 European Chemicals Agency (ECHA) https://echa.europa.eu/information-on-chemicals https://echa.europa.eu/substance-information/-/substanceinfo/100.029.559 https://echa.europa.eu/substance-information/-/substanceinfo/100.048.909 https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/27939 https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/65746 https://www.webmd.com/drugs/2/drug-8714/sulindac-oral/details/list-contraindications Human Metabolome Database (HMDB) http://www.hmdb.ca/metabolites/HMDB0014743 ClinicalTrials.gov https://clinicaltrials.gov/ DailyMed https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=SULINDAC LiverTox https://livertox.nlm.nih.gov/Sulindac.htm NCIT https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C850 FDA Center for Food Safety and Applied Nutrition (CFSAN) https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=IndirectAdditives&id=COPAL FDA Medication Guides https://www.fda.gov/downloads/Drugs/DrugSafety/ucm088573.pdf FDA Orange Book https://www.fda.gov/Drugs/InformationOnDrugs/ucm129662.htm MassBank of North America (MoNA) http://mona.fiehnlab.ucdavis.edu/spectra/browse?inchikey=MLKXDPUZXIRXEP-MFOYZWKCSA-N SpectraBase https://spectrabase.com/compound/CWWr3rlqtWu#4o3OzCJVFn0 https://spectrabase.com/compound/CWWr3rlqtWu#2UVLaPdDnjC https://spectrabase.com/compound/CWWr3rlqtWu#JK28Q1toH7p https://spectrabase.com/compound/CWWr3rlqtWu#6X3JSUWQVQG https://spectrabase.com/compound/CWWr3rlqtWu#9GHFfLUticV https://spectrabase.com/compound/CWWr3rlqtWu#F8CfUOfxb1I https://spectrabase.com/compound/CWWr3rlqtWu#4TFvhe8gTt6 https://spectrabase.com/compound/CWWr3rlqtWu#DGZZWlnROP7 https://spectrabase.com/compound/CWWr3rlqtWu#9TB6iUPTrur https://spectrabase.com/compound/CWWr3rlqtWu#1159Qap0a2h PubMed Health http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0012258/ Show More